Analysts Upbeat On Aurobindo After Strong Earnings
Executive Summary
Analysts are enthusiastic about the US earnings prospects of leading Indian generic firm Aurobindo after the company reported a nearly 20% jump in consolidated net profit for the third quarter, and declared it would focus on digesting its acquisitions.
You may also be interested in...
Duet Or Duel: Will 2019 See More India Pharma Linkages In China?
2018 has seen some interesting Indo-Chinese pharma linkages amid evolving regulations in China and generally improved overall ties between the Asian neighbors. Could the trend stick in 2019 with more Indian firms taking a shot at the world’s second-largest pharma market?
Top US Court Lifts Discovery Stay On Price-Fixing
The US Supreme Court has lifted a stay on document discovery in a multi-state lawsuit in which dozens of generics companies – including Teva, Mylan and Pfizer – are accused of price fixing. The ruling will allow a swathe of documents to be released in what Connecticut’s attorney general has said is potentially “the largest cartel case” in US history.
FDA Approves First Generic Of Daraprim
Daraprim, which saw its price jacked up by 4,000% by former drug company executive Martin Shkreli, now has a competitor with the US Food and Drug Administration’s approval of the first generic version of the nearly seven-decade-old drug used to treat a life-threatening parasitic infection known as toxoplasmosis.